INVESTMENT SECURITIES

6 Months Ended

Mar. 31, 2022

Disclosure Investment Securities Abstract

INVESTMENT SECURITIES

NOTE 10. INVESTMENT SECURITIES

During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.

During the quarter ended June 30, 2021 13,000 of the aforementioned common shares were sold to an unrelated party for $300,000 cash.

During the quarter ended September 30, 2021 18,000 of the aforementioned common shares were sold to an unrelated party for $195,000 cash.

As of March 31, 2022 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company.

On March 31,2022 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of March 31, 2021:

18,300 Common Shares of Oncology Pharma, Inc.
	Basis		Fair Value		Total Unrealized Losses		Net Unrealized Gain or (Loss) realized during the quarter    ended December 31,2021
$	677,100	$	67,710	$	602,985	$	(123,891	)